Search

Displaying results 5711 - 5720 of 10000 in total
  1. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].

  2. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  3. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    As of May 2015, it is in phase III clinical trials for schizophrenia. … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

  4. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  5. Drug

    MK-0777

    go.drugbank.com/drugs/DB12238
    Investigational

    MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.

  6. Drug

    Recombinant Super-Compound Interferon

    go.drugbank.com/drugs/DB15752
    Investigational

    Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.

    Synonyms: rSIFN-co
  7. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging … J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSynonyms: N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide
  8. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for

  9. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  10. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.